<DOC>
	<DOCNO>NCT02531438</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy omadacycline compare moxifloxacin treatment adult community-acquired bacterial pneumonia .</brief_summary>
	<brief_title>Omadacycline v Moxifloxacin Treatment CABP ( EudraCT # 2013-004071-13 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Community-Acquired Infections</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients , age 18 year old sign inform consent Has qualify bacterial pneumonia Female patient must pregnant time enrollment Must agree reliable method birth control study 30 day follow last dose study drug Known suspect hospitalacquired pneumonia Evidence significant immunological disease Has history hypersensitivity allergic reaction tetracycline fluoroquinolone antibiotic Has receive investigational drug within past 30 day Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>